Opko Health, Inc.

311 articles about Opko Health, Inc.

• Opko Health, Inc. Release: Phase 3 Data Supporting Rayaldee As A Treatment For Secondary Hyperparathyroidism In Chronic Kidney Disease To Be Presented At NKF 2015 Spring Clinical Meetings

  3/27/2015

• Opko Health, Inc. Receives Accreditation From College of American Pathologists

  3/18/2015

• Opko Health, Inc. Release: Twelve Months Data Supporting Once-Weekly Dosing Of Hgh-CTP In Growth Hormone Deficient Pediatric Population To Be Presented At ENDO 2015 Conference

  3/3/2015

• Opko Health, Inc. To Announce Fourth Quarter And Full Year 2014 Financial Results On February 27, 2015

  2/26/2015

• Opko Health, Inc. Announces Publication Of 20 Year Outcome Study For Lethal Prostate Cancer Using Kallikrein Biomarkers In 4Kscore Test

  2/23/2015

• Opko Health, Inc. Submits Investigational New Drug Application To Initiate A Phase 2a Trial For Its Long-Acting Coagulation Factor Viia-CTP To Treat Hemophilia

  2/2/2015

• Opko Health, Inc. Launches The 4Kscore Test In Mexico

  1/29/2015

• Opko Health, Inc. And Pfizer Receive Regulatory Clearance For Global Agreement

  1/29/2015

• Opko Health, Inc. Claros1 Analyzer Selected For Development Of A Rapid Lyme Disease Test Under Immuno Technologies NIH Grant

  1/12/2015

• Opko Health, Inc. To Present At The 33rd Annual J.P. Morgan Healthcare Conference

  1/5/2015

• Opko Health, Inc. Rockets After Striking Deal Worth $570 Million With Pfizer

  12/17/2014

• Opko Health, Inc. To Present At The Oppenheimer 25th Annual Healthcare Conference

  12/3/2014

• Insider Buying: Phillip Md Et Al Frost Purchases 40,000 Shares Of Opko Health, Inc. Stock

  11/25/2014

• Opko Health, Inc. Announces Third Quarter Operating And Financial Results

  11/7/2014

• DSG, Inc. And Opko Health, Inc. Enter Into Enterprise Licensing Agreement For Fully Integrated EDC, IWRS, Safety, And Trial Management Solution

  11/4/2014

• Neovasc Inc., An Opko Health, Inc. Investee, Receives FDA Conditional Approval To Initiate TIARA-I Trial In U.S.: A Multinational, Multicenter Early Feasibility Trial Of The Tiaratm Transcatheter Mitral Valve

  10/9/2014

• Opko Health, Inc. Supports National Prostate Cancer Council Legislation

  9/29/2014

• Opko Health, Inc.'s Second Rayaldee Phase 3 Trial Meets Primary Endpoints

  9/23/2014

• Opko Health, Inc. Licensee Tesaro, Inc. Submits New Drug Application for Rolapitant

  9/8/2014

• Opko Health, Inc. Release: Rayaldee Phase 3 Trial Meets Primary Endpoints

  8/12/2014